These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23104650)

  • 21. Aripiprazole in schizophrenia with cocaine dependence: a pilot study.
    Beresford TP; Clapp L; Martin B; Wiberg JL; Alfers J; Beresford HF
    J Clin Psychopharmacol; 2005 Aug; 25(4):363-6. PubMed ID: 16012280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aripiprazole as a potential pharmacotherapy for stimulant dependence: human laboratory studies with d-amphetamine.
    Stoops WW
    Exp Clin Psychopharmacol; 2006 Nov; 14(4):413-21. PubMed ID: 17115868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aripiprazole for the maintenance treatment of bipolar I disorder: A review.
    McIntyre RS
    Clin Ther; 2010; 32 Suppl 1():S32-8. PubMed ID: 20152551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].
    Costentin J
    Encephale; 2009 Feb; 35(1):66-72. PubMed ID: 19250996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.
    Thase ME; Jonas A; Khan A; Bowden CL; Wu X; McQuade RD; Carson WH; Marcus RN; Owen R
    J Clin Psychopharmacol; 2008 Feb; 28(1):13-20. PubMed ID: 18204335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
    J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Aripiprazole: a new atypical antipsychotic drug].
    Fischer B; Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Sep; 72(9):497-502. PubMed ID: 15365912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse.
    Feltenstein MW; Altar CA; See RE
    Biol Psychiatry; 2007 Mar; 61(5):582-90. PubMed ID: 16806092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cariprazine (RGH-188), a D₃-preferring dopamine D₃/D₂ receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats.
    Román V; Gyertyán I; Sághy K; Kiss B; Szombathelyi Z
    Psychopharmacology (Berl); 2013 Mar; 226(2):285-93. PubMed ID: 23138433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
    Leite JV; Guimarães FS; Moreira FA
    Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness.
    Katzman MA
    J Affect Disord; 2011 Jan; 128 Suppl 1():S11-20. PubMed ID: 21220076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Quetiapine in substance use disorders, abuse and dependence possibility: a review].
    Erdoğan S
    Turk Psikiyatri Derg; 2010; 21(2):167-75. PubMed ID: 20514567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open-label study of aripiprazole in nonschizophrenic crack-dependent patients.
    Vorspan F; Bellais L; Keijzer L; Lépine JP
    J Clin Psychopharmacol; 2008 Oct; 28(5):570-2. PubMed ID: 18794657
    [No Abstract]   [Full Text] [Related]  

  • 36. Effectiveness of aripiprazole for medication overuse headache: a case report.
    Yamada K; Makihara Y; Imamura Y
    Psychiatry Clin Neurosci; 2011 Apr; 65(3):296-8. PubMed ID: 21507137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subjective, cognitive/psychomotor, and physiological effects of aripiprazole in Chinese light and heavy smokers.
    Liu Y; Sun HQ; Bao YP; Li SX; Beveridge TJ; Di XL; Yang FD; Lu L
    Drug Alcohol Depend; 2009 Apr; 101(1-2):42-52. PubMed ID: 19070440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of aripiprazole in alcohol dependence.
    Martinotti G; Di Nicola M; Janiri L
    Am J Drug Alcohol Abuse; 2007; 33(3):393-401. PubMed ID: 17613966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial.
    Tramontina S; Zeni CP; Ketzer CR; Pheula GF; Narvaez J; Rohde LA
    J Clin Psychiatry; 2009 Apr; 70(5):756-64. PubMed ID: 19389329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacotherapies for adolescent substance use disorders.
    Simkin DR; Grenoble S
    Child Adolesc Psychiatr Clin N Am; 2010 Jul; 19(3):591-608. PubMed ID: 20682223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.